Results 191 to 200 of about 168,862 (349)

Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto, Samaneh Ghadami, Kristen Dellinger   +2 more
wiley   +1 more source

Relapsed Chronic Lymphocytic Leukemia Heralded by Parathyroid Hormone Related Peptide-Mediated Hypercalcemia. [PDF]

Clin Case Rep
Tallavajhala S, Lee J, Dougherty SC, Kurpiel BR, Portell CA.   +4 more
europepmc   +1 more source

Structure and function of the hematopoietic cancer niche focus on chronic lymphocytic leukemia [PDF]

, 2012
Thomas J. Kipps
openalex   +1 more source

Chronic lymphocytic leukemia

Hematology, 2015
openaire   +2 more sources

Blue‐Gray Papules on the Chest and Face

JEADV Clinical Practice, EarlyView.
Sanjana Likki, Kevin Lee, Priyadharsini Nagarajan, Doina Ivan, Woo Cheal Cho, Fiorinda Muhaj   +5 more
wiley   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ibrahim EIK, Friberg LE.
europepmc   +1 more source

Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this
Marçal Bravo Padros, Daniela J. Conrado, Kamal Srinivasan, Lutz O. Harnisch, John D. Davis, Min Zhu   +5 more
wiley   +1 more source

Eltrombopag for Refractory Immune Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Int Med Case Rep J
Alsalman M.
europepmc   +1 more source

THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES

, 2009
Marta Coscia, Francesca Pantaleoni, Chiara Riganti, Micol Maria Rigoni, Silvia Peola, Candida Vitale, Daniela Drandi, Marco Ladetto, Amalia Bosìa, Mario Boccadoro, Massimo Massaia   +10 more
openalex   +1 more source